Invention Grant
- Patent Title: Combination therapy of immunotoxin and checkpoint inhibitor
-
Application No.: US15773418Application Date: 2016-11-04
-
Publication No.: US11065332B2Publication Date: 2021-07-20
- Inventor: Darell Bigner , Vidyalakshmi Chandramohan , Smita Nair , Matthias Gromeier , Xuhui Bao , Ira H. Pastan
- Applicant: DUKE UNIVERSITY , THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
- Applicant Address: US NC Durham; US MD Rockville
- Assignee: DUKE UNIVERSITY,THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
- Current Assignee: DUKE UNIVERSITY,THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
- Current Assignee Address: US NC Durham; US MD Rockville
- Agency: Banner & Witcoff, Ltd.
- International Application: PCT/US2016/060469 WO 20161104
- International Announcement: WO2017/079520 WO 20170511
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K47/68 ; A61P35/00 ; A61K38/16 ; A61K39/00
Abstract:
Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.
Public/Granted literature
- US20180311346A1 COMBINATION THERAPY OF IMMUNOTOXIN AND CHECKPOINT INHIBITOR Public/Granted day:2018-11-01
Information query
